El.En. — Investor Presentation 2023

Nov 15, 2023

1

COMPANY PRESENTATION

IntermonteMadrid European Midcap Event

November 16th, 2023

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forwardlooking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forwardlooking statements. The Company undertakes no obligation about the contents nor to update the forwardlooking statements to reflect events or circumstances that may arise after the date hereof.

1.Overview2.Markets and Growth drivers 3.Innovation: products & applications 4.FDA clearance for Accure laser5.Financial Highlights 6.Current Outlook 7.Multiples & Comparables

OVERVIEW

^A PRIMARY PLAYER PROVIDING MEDICAL, INDUSTRIAL ANDCONSERVATION LASER SOLUTIONS WORLDWIDE

World Class Hi-Tech company

Hi-Tech industrial group providing laser solutions with proprietary technologies and know how developed over ⁴⁰ years

Listed on Milan's Stock Exchange Star segment since year ²⁰⁰⁰ and member of Euronext Tech Leaders

Within Worldwide leaders in its space

Active worldwide on several laser application segments andmarkets…

…progressively widening its worldwide presence achieving continuous growth over the years

WE CREATE LIGHT,ENERGY,WAVES

MEDICAL

Our energy based systems improve people's well-being and life quality.

In the SURGICAL SECTOR, our minimally invasive technology systems minimize pain, side effects and risks of surgical procedures and hospitalization days.

In the AESTHETIC SECTOR, our systems satisfy the growing desire of individuals to improve their appearance also reducing pathological or painful imperfections.

INDUSTRIAL

Our LASER CUTTING and MARKING SYSTEMS Improve the productivity of our customers manufacturing plants also limiting the environmental impact of manufacturing processes minimizing waste, fumes generatedby the process, use of chemical additives, andallowing to eliminate the need for inks, solvents or glues within the process.

CONSERVATION

Our LASER SYSTEMS PRESERVE artworks of the universal heritage of our communities.

ENVIRONMENT2

Photovoltaic systems active in ²¹

4New plants installed in ²²

9%Self-generated energy or from renewable sources

7

OUR HISTORY

80s

Production of CO² lasers for dermatology, surgery and therapy

1981

Incorporation of El.En.S.n.c

Development of short pulse Nd:YAG lasers for dentistry and minimally invasive surgery treatments

1990 - ¹⁹⁹³

Incorporation of Deka MELA S.r.l., Lasit S.p.A. ^eCutlite Penta S.r.l.

1998

Smartepil (Deka Mela S.r.l.) - first long pulse Nd:Yag laser for dermatology and hair removal

2000

El.En.S.p.A.listed on the italian stock market

2002

Smartlipo (Deka Mela S.r.l.laserlipolisi®: localized removal of adipose deposits with minimally invasive treatment

Acquisition of Cynosure Inc.

2003

Smartxide DOT® Therapy (Deka Mela S.r.l.) dermatological surgery, anti-aging treatments,removal of pigmented lesions and scars

Acquisition of Asclepion GmbH

2004

Acquisition of Quanta System

2005

Acquisition of Asa

Cynosure IPO on Nasdaq

2007

Incorporation of a JV in China: Wuhan Penta Chutian Co.Ltd

Incorporation of Cutlite Do Brasil Alta Tecnologia Ltda

2008

Mediostar XT (Asclepion GmbH) esthetics and hair removal.

Industrial sector El.En.– creation of the BLADE RF CO²BLADE RF laser sources family

Litho (Quanta System S.p.A.) surgical, treatment of kidney stones

2009

Plus RF (Cutlite Penta S.r.l.) with RF El.En. sources for metacrilate and wood cutting systems

Incorporation of Esthelogue S.r.l.

2010

Smartxide² (Deka Mela S.r.l.) laser system with CO2 radio frequency (RF) laser sources for dermatological surgery and aesthetics

2011

Mediostar Next (Asclepion GmbH) aesthetics, hair removal

OUR HISTORY

2012

Monna Lisa TouchTM (Deka Mela S.r.l.) for the treatment of vaginal atrophy

Cyber (Quanta System S.p.A.) surgery, Lithotripsy and BPH

2013

Incorporation of second JV Penta Laser Equipment (Wenzhou) Co.Ltd

2016

Motus AX with Moveo (Deka Mela S.r.l.) hair removal,removal of pigmented lesions

Juliet® (Asclepion GmbH) for the treatment of vaginal atrophy

Deka M.E.L.A.S.r.l.and Quanta SystemS.p.A.join their commercial brand names intoReinassance® for the Italian market

2019

The Chinese subsidiary Penta Laser Equipment (Wenzhou) Co.Ltd incorporates Penta Laser Technology (Shangdong) Co.Ltd

Acquisition by Quanta System of Galli S.r.l. a precision mechanical components manufacturing facility.

2015

Bolt (Penta Chutian ^e Wenzhou - China) enhanced system for laser metal cutting

Discovery Pico (Quanta System S.p.A.) tattoo and pigmented lesions removal and dermatological treatments

HIRO TT (ASA S.r.l.) painful pathologies of the muscle and skeleton

Fiber Plus (Cutlite Penta S.r.l.) first metal cutting laser system equipped with fiber laser source

2017

Industrial sector RF ¹²²² CO² RF laser source "The Big Boy"

2018

ONDA Coolwaves®(Deka Mela S.r.l.) the first microwaves technology system for body contouring

2020

Schwarzy (magnetotherapy) RedTouch (dermatology) Again (hair removal)Dr.Arnold(magnetotherapy)

2021

Lasit Laser Polska incorporated by Lasit in Poland

Glide (dermatology) Chrome Laser Station(dermatology)

9

EL.EN. WORLDWIDE

GROWTH HISTORY

MARKETS AND GROWTH DRIVERS

LASER SURGERY MARKET TRENDS

MINIMALLY INVASIVE SURGERIES:

• Painless procedures
• Lower risks and side effects
• Shorter hospital stays/Faster recovery
• Savings by Private & National Health Systems
• Attractive ROI for surgical services providers
• Rapidly Growing Urology laser market

MEDICAL AESTHETICS MARKET TRENDS

• Aging demographics and increasing focus on improving appearance and youthfulness;
• Growing interest in non-invasive or minimally invasive procedures and awareness of energybased aesthetic treatments
• Growing global obesity rate
• Reductions in procedure costs, attracting a broader patient base
• Normalization and social acceptance of cosmetic procedures
• Rapid growth expected

MARKET RESEARCHES GROWTH ESTIMATES

GLOBAL MEDICAL LASER MARKET

2 0 2 8
2 0 2 9 o
2 0 3 2 o
2 0 3 0 o

With an estimated market size of ≃\$5 Bln in 2021 including:

• Ophthalmology
• Dermatology
• Aesthetics
• Surgical
• Gynecology - Urology
• Cardiovascular
• Dentistry

EXPECTED GROWTH IN COSMETIC MARKET

Research and Markets CAGR 15,2% to 2027 The business research company CAGR 19,1% to 2027

INDUSTRIAL LASER MARKET TREND

Laser cutting applications:

• Laser power increase + Cost reduction: enhanced flexibility, productivity and quality standards in manufacturing processes
• New application verticals
• Building and construction

Laser marking:

• Products identification and traceability
• Minimal environmental impact

Laser processing market:

• Size: \$17,48 billion in 2021
• Expected CAGR to 2030: 9,1%

INNOVATION: PRODUCTS & APPLICATIONS

HAIR REMOVAL DEVICES

Again Pro Motus

19

BODY CONTOURING DEVICES

SKIN DEVICES

Discovery Pico Smart Pico

Unique high end system for laser tattoo removal

Luxea

The ultimate multi application and multi technology platform

RED Touch Pro

The system for neocollagenesis and tissue regeneration

One of the main worldwide players in high power medical fiber lasers

Our novel disruptive technology for the most effective stones micro fragmentation

MONALISA TOUCHGLIDE - DUOGLIDE

Novel CO2 device for dermatology and gynecology featuring an additional 1540nm laser source

PHYSIOTHERAPY

MiS (MLS Family) For degenerative neuropathies

INDUSTRIAL LASERS SYSTEMS

STEEL CUTTING

12 kW Average power in 2022 sales

40 kW systems installed in 2022

Testing 60kw systems

LASER CUTTING SYSTEMSOFFER IN CHINA

FDA CLEARANCE FOR ACCURE LASER

FDA Clears the revolutionary Accure Laser

• Disruptive technology with active IP portfolio in the vast, global acne market
• Positive safety profile & clinical results; non-drug based with expected durable outcomes
• World-class team: Dr. Rox Anderson: Co-Founder; Chief Scientific & Medical Officer
• CE Marked

FDA Clears the revolutionary Accure Laser

FDA Clears the revolutionary Accure Laser

FINANCIAL HIGHLIGHTS

INCOME STATEMENT – FY 2022

'0 E 0 0 u r o	/ / 3 1 1 2 2 1	%	/ / 3 1 1 2 2 2	%	% V a r.
			d d i t u n a u e
d l i M e c a	3 2 9 0 1 1.	% 5 4, 5	3 8 2 0 6 3	6, % 5 7	2 2, % 7
d l I i t n u s r a	2 6 0 1 1 2	4 % 5, 5	2 9 1. 1 8 5	4 3, 3 %	1 2, 1 %
R e v e n u e s	5 7 1 4 0 2	1 0 0 0 % ,	6 7 3 5 8 1	1 0 0 0 % ,	1 7 9 % ,
i G r o s s m a r g n	2 1 2 0 7 3	% 3 7 1 ,	2 4 9 6 9 5	% 3 7 1 ,	% 1 7 7 ,
i O E t p e r a n g x p e n s e s	4 7 8 1 2	% 8 4 ,	5 6 2 5 0	% 8 4 ,	% 1 7 6 ,
f f S t a e s p e n s e s	8 4 1 0 7	1 4 % 7 ,	9 8 1 9 4	1 4 6 % ,	1 6 % 7 ,
E B I T D A	8 0 0 9 1	1 4 0 % ,	9 5 2 5 1	1 4 1 % ,	1 8 9 % ,
l D t. e p r. a m o r a c c r u a s , ,	1 5 2 3 4	% 2 7 ,	1 4 2 5 0	% 2 1 ,	% 6 5 - ,
E B I T	6 8 8 4 5	% 1 1, 4	8 0 0 1 1	2 0 % 1 ,	2 9 % 4 ,
f ( ) h N i i t e n a n c. n c o m e c a r g e s	1 7 5 2	0 3 % ,	( ) 1 9 3 4	0 3 % - ,
h ( ) O i t t e r n c o m e e x p e n s e n e	( ) 1 8 5	0 0 % ,	( ) 7 9	0 0 % ,	5 7 5 % - ,
E B T	6 6 4 2 4	% 1 1, 6	7 8 9 8 8	% 1 1, 7	% 1 8 9 ,
I t n c o m e a x e s	3 0 0 1 7	3 0 % ,	9 9 3 1 5	3 0 % ,	3 % 1 5 ,
M i i i t n o r e s	3 6 8 8	0 6 % ,	3 9 2 5	0 6 % ,	6 4 % ,
N E T I N C O M E	4 5 4 3 6	% 8 0 ,	5 5 1 1 1	% 8 2 ,	% 2 1, 3

BALANCE SHEET– FY 2022

/ / 3 2 2 1 1 1	/ / 3 2 2 2 1 1	% V a r.
	d t t r e s a e
1 3 6 6 4 8	1 6 5 7 8 6	% 2 1 3 ,
1 4 4 6 4 1	2 0 0 5 3 6	% 3 8 6 ,
( 9 1 2 8 7	( 8 0 1 5 4	1 2 2 % - ,
6 6 1 1 5 7	3 6 3 7 5	3 9 % 4 - ,
1 8 0 7 6	1 8 0 7 7	% 0 0 ,
2 8 7 7 0 1	3 4 3 4 5 5	% 1 9 4 ,
1 7 1 9 3 5	2 6 8 0 9 2	5 5 9 % ,
2 3 % 5 ,	2 9 8 % ,
% 3 7 7 ,	% 3 0 2 ,
2 3 1 5 0	2 8 5 1 4
	)	)

Income Statement – 9M 2023

'0 E 0 0 r o u	/ / 3 0 0 9 2 2	%	/ / 3 0 0 9 2 3	%	% V a r.
	d d i t u n a u e		d d i t u n a u e
d l M i e c a	2 7 0 5 2 9	5 5, 9 %	2 8 7 9 5 4	5 8, 4 %	6, 4 %
d l I i t n s r a u	2 1 3 8 2 0	% 4 4, 1	2 0 5 0 5 7	% 4 1, 6	% 4, 1 -
R e v e n u e s	8 3 8 4 4 4	0 0 0 % 1 ,	9 3 0 4 1 1	0 0 0 % 1 ,	8 % 1,
G i r o s s m a r g n	9 9 6 1 7 4	3 % 7 1 ,	8 2 1 7 1 1	3 8 0 % ,	3 % 4 ,
O i E t p e r a n g x p e n s e s	4 1 1 1 5	8 6 % ,	4 4 3 9 3	9 0 % ,	6 9 % ,
f f S t a e s p e n s e s	7 0 4 2 1	1 4 5 % ,	8 0 9 3 8	1 6 4 % ,	1 4 9 % ,
E B I T D A	6 7 5 6 4	% 1 3 9 ,	6 1 8 8 0	% 1 2 6 ,	% 8 4 - ,
l D t. e p r. a m o r a c c r a s u , ,	9 6 4 0	% 2 0 ,	1 0 1 0 2	% 2 0 ,	% 4 8 ,
E B I T	5 7 9 2 4	% 1 2 0 ,	5 1 7 7 8	% 1 0 5 ,	% 1 0 6 - ,
( ) f h i i N t e n a n c. n c o m e c a r g e s	( ) 7	0 0 % ,	( ) 8 6 6	0 2 % - ,	3 0 8 8 % 1 7 ,
( ) h O i t t e r n c o m e e x p e n s e n e	3	0 0 % ,	( ) 2 4	0 0 % ,
E B T	9 2 0 5 7	2 0 % 1 ,	0 8 0 5 7	0 3 % 1 ,	2 2 % 1 - ,
	/ / 3 1 1 2 2 2		/ / 3 0 0 9 2 3 d d i t n a e u u
f l i i i i N t t e n a n c a p o s o n	7 5 3 6 3		3 2 0 8 9

Income Statement – Q3 2023

'0 0 0 E u r o	Q 3 2 0 2 2 -	% Q 3 2 0 2 3 -		%	% V a r.
	d d i t u n a u e		d d i t u n a u e
R e e n e s v u	1 5 7 3 7 4	% 1 0 0 0 ,	1 4 7 3 8 6	% 1 0 0 0 ,	% 6 3 - ,
i G r o s s m a r g n	5 7 6 4 1	3 6 6 % ,	5 5 7 3 8	3 7 8 % ,	3 3 % - ,
O i E t p e r a n g x p e n s e s	1 3 8 6 4	8 8 % ,	1 3 2 7 7	9 3 % ,	0 % 7 - ,
f f S t a e s p e n s e s	2 3 4 3 9	% 1 4 9 ,	2 5 7 4 1	% 1 7 5 ,	% 9 8 ,
E B I T D A	2 0 3 3 7	% 1 2 9 ,	1 6 2 2 6	% 1 1 0 ,	% 2 0 2 - ,
l D t e p r. a m o r a c c r a s u , .,	3 8 0 4	% 2 4 ,	3 3 2 2	% 2 3 ,	% 1 2 7 - ,
E B I T	1 6 3 3 5	1 0 % 5 ,	1 2 9 0 3	8 8 % ,	2 2 0 % - ,
f ( ) h i i N t e n a n c n c o m e c a r g e s	( ) 2 6 1	0 2 % - ,	6 2 1	0 % 1 ,
( ) h i O t t e r n c o m e e x p e n s e n e	( ) 4	% 0 0 ,	( ) 3 8	% 0 0 ,	% 7 5 4 9 ,
E B T	1 6 2 6 7	1 0 3 % ,	1 3 0 2 8	8 8 % ,	1 9 9 % - ,

50 mln9 months

Revenue breakdown by area

CURRENT OUTLOOK

MULTIPLES & COMPARABLES

MULTIPLES

k h l 's h d i S E t t o c o e r q u y p e r s a r e	4 5 ,
/ k l d i j. P B V A r c e o o a e u	2 0 ,
/ ( ) 9 0 % E V E B I T E B I T	1 0 9 ,
/ ( ) l l E V S 9 0 % S a e s a e s	1, 1

l. k C E E M t n a r e a p	3 0 9 @ 7 ,	€ 9 1 4 ,
f l i i i i N t t e n a n c a p o s o n	@ 3 2 1 ,	/ / 3 0 0 9 2 3
/ l l i i i F t t t n a n c a n v e s m e n s m e r m	@ 2 3 6 ,	/ / 3 0 0 9 2 3
i l E V t n e r p r s e a u e	6 7 5 2 ,

h , Se 3 0 2 0 2 3 t. t p
	ic Pr No 1 5, e o n v.	Re ve nu e	% Va r.	E B I T	% E B I T	M K. Ca p.	E V	/ Sa le E V s	/ E V E B I T	/ k P Bo o
/ d ica l he ic M Ae t t e s	2 0 2 3		Re v.					( *)	( *)	lu Va e
( ) Cu 2 te ra	\$ 2, 2 3	\$ 6 1 1	% -5	\$ ( ) 3 5	6 % -4	\$ 4 4	\$ 2 5 1	1, 1	n. a.	n. a.
de In M o	\$ 2 0, 9 7	\$ 3 6 5	1 4 %	\$ 1 4 4	4 0 %	\$ 1. 7 4 0	\$ 1. 0 6 7	2, 2	5, 6	2, 4
l h Be He ty t au a	\$ 1, 3 9	\$ 3 0 1	% 1 3	\$ ( ) 1 1 3	% -3 7	\$ 1 8 5	\$ 3 7 7	0, 9	n. a.	2, 1
( ) Ve 2 nu s	\$ 1, 8 3	\$ 4 1	-2 4 %	\$ ( ) 1 4	-3 4 %	\$ 1 0	\$ 8 8	1, 1	n. a.	n. a.
d l ( ) S isr M ica 2 am e	\$ 0, 7 4	\$ 1 7 2	-2 %	\$ 2 2	1 3 %	\$ 3 4 7	\$ 3 3 3	1, 0	7, 7	0, 8
du ia l In tr s
ho I G ics Co P P to n	\$ 9 2 6 5,	\$ 9 8 9	-1 0 %	\$ 2 0 3	2 1 %	\$ 4. 4 0 7	\$ 3. 4 0 6	2, 6	1 2, 6	1, 9
's Ha La n se r	¥ 2 2, 9 4	¥ 9. 3 4 4	-1 1 %	¥ 5 9 9	6 %	¥ 2 4. 0 2 0	¥ 2 3. 7 0 6	1, 9	2 9, 8	1, 4
( ) ic 2 By tr s on	C 9 6 H F 4	C 6 8 H F 4	3 %	C 2 H F 5	% 5	C 9 0 6 H F	C 9 H F 5 1	0, 6	0, 3 1	3 1,
l. ( ) E En 1	€ 9, 1 4	€ 9 3 4	2 %	€ 2 5	% 1 1	€ 3 7 1	€ 6 7 5	1, 1	0, 9 1	2, 0

(1) EV and multiplies as for previous slide

(2) Financials on June 30th, 2023

(*) Revenue,Ebit and earnings annualized

COMPARABLES

44

CONTACTS

El.En. S.P.A.Enrico RomagnoliInvestor Relations Managertel. +39 055-8826807E-mail: finance@elen.it

POLYTEMS HIR

Financial Communication, IR and Press OfficeBianca Fersini Mastelloni - b.fersini@polytemshir.it Silvia Marongiu s.marongiu@polytemshir.itTel. +39 06-69923324